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Abstract : Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, primarily occurs 
during childhood between the ages of 3 and 15 years and is the most common form of systemic vasculitis in chil-
dren ; its occurrence in adults has been rarely reported. Such low incidence could be attributable to either un-
der-diagnosis or misdiagnosis. Thus, not only pediatricians but also physicians should be able to diagnose IgAV 
accurately to manage the patients appropriately and avoid its associated complications. In addition, treatment 
of adult onset IgAV with renal involvement has not been fully established yet. We describe here a case of adult 
onset IgAV complicated by proteinuria and pharyngitis, which was cured by no specific treatment. J. Med. Invest. 
66 : 344-346, August, 2019
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INTRODUCTION
 
Immunoglobulin A vasculitis (IgAV), formerly known as He-
noch-Schönlein purpura (1), primarily occurs during childhood 
between the ages of 3 and 15 years and is the most common form 
of systemic vasculitis in children, with it being diagnosed in over 
90% of systemic vasculitis cases (1, 2, 3) ; its occurrence in adults 
has been rarely reported (4). Such low incidence could be attrib-
utable to either under-diagnosis or misdiagnosis.
Adult onset IgAV is known to be associated with worse renal 
outcomes in contrast to those in children, although the clinical 
manifestations have not been fully characterized (5, 6). Thus, not 
only pediatricians but also physicians should be able to diagnose 
IgAV accurately to manage the patients appropriately and avoid 
its associated complications. In addition, treatment of adult onset 
IgAV with renal involvement has not been fully established yet. 
To this end, we describe here a case of adult onset IgAV compli-
cated by proteinuria and pharyngitis, which was cured by no 
specific treatment. 
CASE
A 20-year-old man with a history of bronchial asthma present-
ed at our hospital with nausea and had noticed skin eruptions on 
the lower extremities for the past 3 days (Figures 1A). He also 
had a sore throat for the past 5 days and fatigue in the knees and 
lower legs. Physical examination of the patient demonstrated 
palpable purpuric eruptions on the lower extremities (Figure 
1) and a slight reddish throat. The patient’s blood pressure was 
122/68 mmHg, pulse, 98 per minute, and body temperature, 
37.8℃. Blood examination indicated systemic inflammation 
with elevated white blood cells, 11900/µL and fibrinogen, 490 
mg/dL, with a positive test for anti-streptolysin O antibody, 
The Journal of Medical Investigation    Vol. 66  2019
　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　
Received for publication December 6, 2018 ; accepted May 9, 2019.
Address correspondence and reprint requests to Shusuke Yagi, MD, 
PhD, Department of Cardiovascular Medicine, Tokushima University 
Graduate School of Biomedical Sciences, Tokushima, 3-18-15 Kuramo-
to-cho, Tokushima 770-8503, Japan and Fax : +81-88-633-7894. Figure 1.　A : Images of palpable purpuric eruptions on the lower 
extremities (A : front, B: back, C : close image of a purpuric eruption)
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suggesting bacterial infection with Streptococcus pyogenes, result-
ing in pharyngitis. Serum level of creatinine (0.7 mg/dL) was 
normal ; however, urinalysis revealed proteinuria of 1+ without 
microscopic hematuria. His serum IgA levels were not elevated 
(317 mg/dL ; normal range, 110–410 mg/dL). Factor XIII level 
was decreased to 43% (normal range, 70–140%). A skin biopsy 
showed inflammatory infiltrates around the superficial blood 
vessels but no nuclear dust and focal fibrinoid necrosis. Direct 
immunofluorescent staining of IgA showed IgA deposition in the 
vascular media indicating a diagnosis of IgAV. 
According to the guidelines, we diagnosed him with possible 
IgAV due to palpable purpura with the biopsy showing granu-
locytes in the walls of small arterioles and venules, arthritis/
arthralgia (acute onset), and renal involvement (proteinuria) 
although he was only 20 years of age and had not experienced 
any acute abdominal pain (7, 8). 
He was administered 500 mg/day of acetaminophen. In 14 
days, his symptoms and purpura completely disappeared, and he 
stopped visiting the hospital for follow-up. He reports feeling well 
one month after his visiting.
DISCUSSION
IgAV is a type of small vessel vasculitis mediated by IgA-im-
mune complex deposition, which is characterized by the clinical 
tetrad of non-thrombocytopenic palpable purpura, abdominal 
pain, arthritis, and renal involvement, and is primarily a child-
hood disease. In a population-based study, the annual incidence 
was reported to be approximately 10–20 per 100,000 in chil-
dren < 17 years of age, with a peak incidence of 70 per 100,000 
in children between the ages of four to seven years (4, 9, 10). In 
contrast, IgAV is less common in adults (2.2 per 100,000) (11), 
although the annual incidence of IgAV in the young adults or 
elderly has not been completely elucidated because of heterogene-
ity of the study population. Recent retrospective studies showed 
that 25 to 30 percent of patients with IgAV were adults (5, 6), 
indicating that adult onset IgAV might be under-diagnosed or 
misdiagnosed due to its rarity. 
Adult onset IgAV is associated with an increased risk for 
developing significant renal involvement, including higher fre-
quency of nephrotic syndrome, hypertension, an elevated serum 
creatinine level, and end-stage renal disease compared with the 
pediatric onset IgAV (12). In particular, elderly patients were 
associated with a low incidence of prior infection and presence 
of arthritis and increased incidence of hypertension and high 
serum IgA levels (13, 14). 
Typically, the onset of disease in pediatric patients is preceded 
by an upper respiratory tract infection (8). The patient experi-
enced vasculitis symptoms 2 days after the prior infection. The 
incubation period may be shorter than that in usual cases. IgAV 
follows an infection in two-thirds of the cases, with disease onset 
at an average of 3–10 days after the start of the infection symp-
toms (15). The incubation period may depend on the patients’ 
health condition and bacterial virulence.
The decrease in the Factor XIII levels was associated with an 
increased severity of complications, including nephritis and gas-
trointestinal involvement, and increase in the Factor XIII levels 
was associated with the rate of recovery (16). Factor XIII may 
be degraded by proteases from leukocytes or consumed around 
the affected vessels, resulting in decreased Factor XIII activity 
in IgAV patients (17). Thus, the Factor XIII level can serve as a 
risk assessment biomarker for IgAV. However, the difference in 
the degree of Factor XIII deficiency between adult and pediatric 
patients with IgAV has not been elucidated.
The diagnosis of IgAV with renal involvement is typically 
based on the clinical presentation. IgAV is confirmed on the 
detection of IgA deposition in the skin or kidney by immunofluo-
rescence microscopy. Differential diagnosis of palpable purpura 
includes other systemic autoimmune diseases (hypersensitivity 
vasculitis, cryoglobulinemia, systemic lupus erythematosus, and 
thrombocytopenic purpura). In this case, IgAV was confirmed 
by skin biopsy, although we did not perform clinical laboratory 
tests, including testing for autoantibodies. A renal biopsy can 
be performed to establish the diagnosis ; however, this invasive 
procedure is considered only for patients with uncertain diagno-
sis or those with more severe renal involvement (e.g., proteinuria 
greater than 1 g/day and/or renal function impairment ; www.
uptodate.com).
In contrast to other types of systemic vasculitis, IgAV is 
self-limiting and most patients recover from it spontaneously. 
Thus, the management primarily involves supportive care and 
includes adequate hydration, rest, and symptomatic relief of pain 
in the majority of cases. There has been no report evaluating the 
treatment approaches for adult onset IgAV, and the use of gluco-
corticoids or immunosuppressants is controversial based on the 
evidence from studies involving children (3). It has been reported 
that glucocorticoid therapy increases the rate of resolution of the 
Figure 2.　Microscopic findings of skin biopsy (hematoxylin and eosin 
staining) showing inflammatory infiltrate around the superficial 
blood vessels (A : low magnified image, B : high magnified image). 
Direct immunofluorescent staining showing IgA positive cells in the 
vascular media (Green : IgA deposition ; Blue : nucleus stained with 
4',6-diamidino-2-phenylindole)
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arthritis and abdominal pain ; however, it does not appear to 
prevent recurrence of the disease (18). Thus, routine glucocorti-
coid therapy for patients with IgAV to treat symptoms or prevent 
renal or gastrointestinal complications is not recommended. 
Glucocorticoid therapy may be recommended only for patients 
with nephrotic syndrome and with symptoms significant enough 
to affect their oral intake, interfere with their ability to ambulate 
and perform activities of daily living, and/or require hospitaliza-
tion (www.uptodate.com).
Altogether, we presented a case of adult-onset IgAV compli-
cated by proteinuria and pharyngitis. We conclude that physi-
cians should be aware of IgAV in the differential diagnoses of 
leg purpura not only in children but also adults, especially in 
patients with upper respiratory tract infection. Palpable purpu-
ra following upper respiratory tract infection could be a cue to 
suspect IgAV ; thus, precise physical examination in such cases 
is needed. 
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